Creative Medical Technology Holdings, Inc. (CELZ) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated April 29, 2022, reports a material definitive agreement and unregistered sale of equity securities by Creative Medical Technology Holdings, Inc. The transaction was completed on May 3, 2022, involving a private placement of securities to institutional investors.
Key Financial Metrics
- Gross Proceeds: Approximately $17,000,000.
- Offering Price: $2.25 per unit (Common Stock/Pre-Funded Warrant and related Common Warrant).
- Placement Agent Fee: $1,360,000 paid to Roth Capital Partners.
- Securities Issued:
- 2,991,669 shares of Common Stock.
- Pre-Funded Warrants to purchase 4,563,887 shares (Exercise Price: $0.0001; No expiration).
- Common Warrants to purchase 15,111,112 shares (Exercise Price: $2.00; 5-year term).
- Placement Agent Warrant to purchase 1,133,333 shares.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, existing debt, or liquidity positions.
Material Changes
The primary material change is the increase in share count and potential dilution resulting from the issuance of approximately 7.55 million shares of Common Stock (direct and via Pre-Funded Warrants) and 16.24 million Common Warrants. The company has entered into a Registration Rights Agreement to register the resale of these securities.
Outlook, Risks, and Contingencies
- Lock-Up Agreements: Directors and officers have agreed not to sell securities for 90 days following the earlier of the effective date of the Registration Statement or the date securities can be sold under Rule 144 without volume limitations.
- Regulatory Compliance: The transaction was effected under Section 4(a)(2) of the Securities Act and Rule 506(b).
- Future Obligations: The Company is obligated to file a Registration Statement with the SEC for the resale of issued securities.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the $1,360,000 placement fee and other transaction costs.
- Confirm the dilution impact on existing shareholders given the issuance of over 16 million warrants.
- Review the full terms of the Securities Purchase Agreement (Exhibit 10.1) for any redemption rights or anti-dilution provisions.
- Monitor the filing status of the Registration Statement required under the Registration Rights Agreement.